[{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Felbinac Trometamol","moa":"COXs","graph1":"Neurology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Felbinac Trometamol","moa":"COXs","graph1":"Neurology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Felbinac Trometamol","moa":"COXs","graph1":"Neurology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Felbinac Trometamol","moa":"COXs","graph1":"Neurology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Shijiazhuang Yiling Pharmaceutical Co.,Ltd."},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XY0206","moa":"FLT3","graph1":"Oncology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"XY0206","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Tigermed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Proswell Medical Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"XY0206","moa":"FLT3","graph1":"Oncology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Proswell Medical Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Proswell Medical Corporation"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C XY0206","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Bio-008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Jinlida","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Shijiazhuang Yiling Pharmaceutical Co.,Ltd."},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Xuanwu Hospital, Beijing","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Phenlarmide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Xuanwu Hospital, Beijing","highestDevelopmentStatusID":"6","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Xuanwu Hospital, Beijing"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"XY03-EA","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XY03-EA","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ First Affiliated Hospital, Sun Yat-Sen University","highestDevelopmentStatusID":"9","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ First Affiliated Hospital, Sun Yat-Sen University"},{"orgOrder":0,"company":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"XY0206","moa":"FLT3","graph1":"Oncology","graph2":"Phase III","graph3":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. \/ Undisclosed"}]
	
		
			
Find Clinical Drug Pipeline Developments & Deals by Shijiazhuang Yiling Pharmaceutical Co.,Ltd. 
		
	 
	
	
		
								
						
					
					
						
					
							
				
									
						
							
															
									Filters
										 
									
										× 
										FILTER:
										
																									
															
																Company Name 
																															
															
														 
																												
															Year  
															
														 
																												
															DEALS // DEV. 
															
														 
																												
															Country 
															
														 
																												
															
																Sponsor 
																															
															
														 
																												
															Therapeutic Area 
															
														 
																												
															Study Phase 
															
														 
																												
															Deal Type 
															
														 
																												
															Product Type 
															
														 
																												
															Dosage Form 
															
														 
																												
															Lead Product 
															
														 
																												
															Target